Pruritus in systemic disease: Mechanisms and management

Dermatologic Clinics

Volumn 20, Issue 3, 2002, Pages 459-472

  Etter, Lawrence ^a   Myers, Sarah A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANTIHISTAMINIC AGENT; BOMBESIN; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; CHOLECYSTOKININ; CHYMASE; COLESTYRAMINE; EMLA; ENDOTHELIN; HISTAMINE; INTERLEUKIN 2; INTERMEDIN; LEUKOTRIENE; NALTREXONE; NEUROKININ; NEUROPEPTIDE; NEUROTENSIN; ONDANSETRON; OPIATE DERIVATIVE; PAROXETINE; PROSTAGLANDIN; SEROTONIN; SEROTONIN ANTAGONIST; SOMATOSTATIN; SUBSTANCE P; TRYPTASE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANAMNESIS; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; ENDOCRINE DISEASE; HEPATOBILIARY DISEASE; HODGKIN DISEASE; HUMAN; IRON DEFICIENCY ANEMIA; KIDNEY TRANSPLANTATION; LABORATORY TEST; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MASTOCYTOSIS; METABOLIC DISORDER; MYCOSIS FUNGOIDES; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHOTOTHERAPY; PHYSICAL EXAMINATION; PLASMA CELL DYSCRASIA; PLASMAPHERESIS; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REVIEW; SYSTEMIC DISEASE; TRANSCUTANEOUS NERVE STIMULATION; ULTRAVIOLET B RADIATION; CHOLESTASIS; HEMATOLOGIC DISEASE; NEOPLASM;

CHOLESTASIS; ENDOCRINE DISEASES; HEMATOLOGIC DISEASES; HUMAN; KIDNEY FAILURE, CHRONIC; NEOPLASMS; PRURITUS; ENDOCRINE SYSTEM DISEASES; HUMANS;

EID: 0036329505     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00011-6     Document Type: Review

References (137)

1. Pruritus as a manifestation of systemic disorders
2. Itch and pain
3. Understanding pruritus in systemic disease
4. Specific C-receptors for itch in human skin
5. Spinothalamic lamina I neurons selectively sensitive to histamine: A central neural pathway for itch
6. Urge to scratch represented in the human cerebral cortex during itch
7. Processing of histamine-induced itch in the human cerebral cortex: A correlation analysis with dermal reactions
8. Pathophysiology of itching
9. Pruritus in polycythemia vera: Treatment with aspirin and possibility of platelet involvement
10. Pruritus of polycythaemia vera: A place for pizotifen?
11. Histamine and serotonin in uremic pruritus: Effect of ondansetron in CAPD-pruritic patients
12. Studies on pruritogenic and histamine-releasing effects of some putative peptide neurotransmitters
13. Peripheral and central mediators of itch
14. Flare and itch induced by substance P in human skin
15. Itch: Role of prostaglandins
16. 2
17. 2 and a prostaglandin endoperoxide analog
18. Prostaglandins and pruritus
19. 4
20. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-α) at the dermal-epidermal junction
21. Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK 33-824, β-endorphin and morphine
22. Itching after epidural and spinal opiates
23. Pharmacological control of opioid-induced pruritus: A quantitative systematic review of randomized trials
24. The role of proteolytic enzymes in the production of pruritus in man
25. Studies on experimental itch induced by kallikrein and bradykinin
26. Experimental itch in human skin elicited by rat mast cell chymase
27. Pruritus: Pathogenesis, therapy, and significance in systemic disease states
28. Pruritus
29. The diagnostic and therapeutic approach to idiopathic generalized pruritus
30. Generalized pruritus and systemic disease
31. Topical capsaicin for treatment of hemodialysis-related pruritus
32. Renal itch
33. Pruritus in dialysis patients treated with parenteral lidocaine
34. Uremic pruritus
35. UV treatment of uraemic pruritus reduces the vitamin A content of the skin
36. Serum vitamin A levels and pruritus in patients on hemodialysis
37. Cutaneous innervation in chronic renal failure patients
38. Disappearance of uraemic pruritus after lowering dialysate magnesium concentration
39. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia: Disappearance of itching after subtotal parathyroidectomy
40. Randomised crossover trial of naltrexone in uraemic pruritus
41. Identifying effective treatments for uremic pruritus
42. Prurigo nodularis and aluminum overload in maintenance haemodialysis
43. Effects of azelastin on pruritus and plasma histamine levels in hemodialysis patients
44. Relief of uremic pruritus with ultraviolet phototherapy
45. Oral activated charcoal in patients with uremic pruritus
46. Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal
47. Cholestyramine in uraemic pruritus
48. Uremic pruritus: Roles of parathyroid hormone and substance P
49. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial
50. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia
51. Erythropoietin treatment does not improve uremic pruritus
52. Electrical needle therapy of uremic pruritus
53. Pruritus in hepatic cholestasis: Pathogenesis and therapy
54. The "butterfly" sign: A clue to generalized pruritus in a patient with chronic obstructive hepatobiliary disease
55. Pruritus as a symptom of hepatitis C
56. Specific pruritic diseases of pregnancy: A prospective study of 3192 pregnant women
57. Pruritic dermatological conditions in pregnancy
58. Pruritus in advanced internal diseases: Pathogenesis and treatment
59. The pruritus of cholestasis
60. Relief of the pruritus of jaundice with a bile-acid sequestering resin
61. Pruritus in cholestasis: No direct causative role for bile acid retention
62. Elevations in skin tissue levels of bile acids in human cholestasis: Relation to serum levels and to pruritus
63. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis
64. Treatment of pruritus of obstructive jaundice with cholestyramine
65. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads
66. Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy
67. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis
68. Rifampin relieves pruritus in children with cholestatic liver disease
69. Treatment of pruritus in primary biliary cirrhosis with rifampin: Results of a double-blind, crossover, randomized trial
70. The effects of phenobarbital on bile salts and bilirubin in patients with intrahepatic and extrahepatic cholestasis
71. Phototherapy for pruritus in primary biliary cirrhosis
72. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease
73. Opioid antagonists in the treatment of pruritus from cholestatic liver disease
74. Effects of naloxone infusions in patients with the pruritus of cholestasis
75. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis
76. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study
77. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study
78. Codeine for pruritus in primary billiary cirrhosis
79. Subhypnotic doses of propofol relieve pruritus associated with liver disease
80. Ondansetron for pruritus due to cholestasis
81. Relief of cholestatic pruritus by a novel class of drugs: 5-Hydroxytryptamine type 3 (5-HT3) receptor antagonists: Effectiveness of ondansetron
82. Improvement of cholestatic pruritus by ondansetron
83. Cimetidine treatment of pruritus in polycythemia vera
84. Relief of intractable pruritis in polycythaemia rubra vera with cholestyramine
85. Long-term treatment with interferon-α2b for severe pruritus in patients with polycythaemia vera
86. A study of histamine in myeloproliferative disease
87. The use of cimetidine for the treatment of pruritus in polycythemia vera
88. α-interferon for intractable pruritus in polycythaemia vera
89. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa
90. Pruritus and severe iron deficiency in polycythaemia vera
91. Pruritus: A manifestation of iron deficiency
92. Severe pruritus should be a B-symptom in Hodgkin's disease
93. Should the patient with generalized pruritus be evaluated for malignancy?
94. Cimetidine for pruritus in Hodgkin's disease
95. Pruritus and malignancy
96. Pruritic specific cutaneous infiltrates in leukemia and lymphoma
97. Pruritus as a presentation of myelomatosis
98. Cutaneous mastocytosis without clinically obvious skin lesions
99. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis
100. The mast cell and mast cell disease
101. Urticaria pigmentosa responsive to nifedipine
102. Cutaneous manifestations of hyperthyroidism
103. Itching-research has barely scratched the surface
104. Pruritus in diabetes mellitus: Investigation of prevalence and correlation with diabetes control
105. Cutaneous signs of diabetes mellitus
106. Paroxysmal pruritus and multiple sclerosis
107. Paroxysmal itching in multiple sclerosis
108. Skin manifestations associated with tumours of the brain
109. CNS-related itch is hard to treat
110. Poststroke pruritus
111. Unilateral pruritus and Nocardia brain abscess
112. Pruritus, an uncommon but important symptom of systemic carcinoma
113. Pruritus in cancer patients
114. Paroxetine for pruritus in advanced cancer
115. Pruritus as a presenting sign of acquired immunodeficiency syndrome
116. Scratching and fasting: A study of pruritus and anorexia nervosa
117. Paroxetine in a case of psychogenic pruritus and neurotic excoriations
118. Effects of menthol and cold on histamine-induced itch and skin reactions in man
119. Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin
120. Relief of experimentally induced pruritus with a novel eutectic mixture of local anaesthetic agents
121. Effect of topical pramoxine on experimentally induced pruritus in humans
122. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis
123. Self-potentiating allergic contact dermatitis caused by doxepin hydro-chloride cream
124. Allergic contact dermatitis from doxepin cream
125. Capsaicin in dermatologic disease
126. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases
127. Tar
128. Coal tar, pine tar and sulfonated shale oil preparations: Comparative activity, efficacy and safety
129. Transcutaneous electronic nerve stimulation in the treatment of generalized pruritus
130. Evaluation on the antipruritic role of transcutaneous electrical nerve stimulation in the treatment of pruritic dermatoses
131. Cutaneous field stimulation (CFS): A new powerful method to combat itch
132. Cutaneous field stimulation in the treatment of severe itch
133. Mechanism of action of antipruritic drugs
134. Pruritus: Unapproved treatments or indications
135. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist
136. Treatment of pruritus: A new indication for serotonin type 3 receptor antagonists
137. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia